{
  "abstract": "Introduction Aneurysmal subarachnoid hemorrhage (aSAH) is a cause of severe brain injury. In patients who survive the initial rupture, vasospasm and delayed cerebral ischemia (DCI) have been established as markers of morbidity and mortality.Aim of study To evaluate the potential benefit of intravenous (IV) milrinone as a preventive strategy for delayed cerebral ischemia (DCI) following aSAH, and to assess its impact on functional outcomes and mortality.Method We conducted a retrospective cohort study in Colombia on patients with aSAH treated with aneurysm embolization. Patients were divided 2:1 into standard care and standard care plus IV milrinone groups. Outcomes assessed included functional status (mRS ≤3) at discharge and 90 days, mortality, vasospasm, and DCI. Subgroup analysis evaluated milrinone tolerance, need for rescue angioplasty, and infectious complications.Abstract A232 Figure 1Results Among 94 patients, 33 received IV milrinone in addition to standard care; 27.2% did not tolerate it due to hypotension or arrhythmia. Functional outcomes (mRS≤3) were similar between milrinone and control groups at discharge (54.2% vs 59.1%) and 90 days (62.5% vs 60.5%). However, patients with good milrinone tolerance had significantly better outcomes than those without tolerance (54.2% vs 11.1%, p=0.001). DCI was more frequent in the no-milrinone and no-tolerance groups. Mortality was lower in the milrinone group (12.5% vs 26.7%), with significantly higher mortality in patients who did not tolerate milrinone (77.7% vs 12.5%, p=0.001), suggesting tolerance influences prognosis.Abstract A232 Figure 2Conclusion In our study we found that prophylactic treatment with IV milrinone in patients with aSAH was associated with lower occurrence of DCI and lower mortality rates.Conflict of Interest No",
  "authors": [
    {
      "affiliations": [
        "Fundación Oftalmológica de Santander-Clínica Ardila Lülle, Universidad Autónoma de Bucaramanga, Floridablanca, Colombia"
      ],
      "name": "Juan Rendon"
    },
    {
      "affiliations": [
        "Fundación Oftalmológica de Santander-Clínica Ardila Lülle, Floridablanca, Colombia"
      ],
      "name": "Daniela Arias Ramírez"
    },
    {
      "affiliations": [
        "Fundación Oftalmológica de Santander-Clínica Ardila Lülle, Universidad Autónoma de Bucaramanga, Floridablanca, Colombia"
      ],
      "name": "Camilo Alvarado Bedoya"
    },
    {
      "affiliations": [
        "Fundación Oftalmológica de Santander, Floridablanca, Colombia"
      ],
      "name": "María Estévez Ochoa"
    },
    {
      "affiliations": [
        "Universidad Autónoma de Bucaramanga, Floridablanca, Colombia"
      ],
      "name": "Adriana Reyes Gonzalez"
    },
    {
      "affiliations": [
        "Fundación Oftalmológica de Santander-Clínica Ardila Lülle, Floridablanca, Colombia"
      ],
      "name": "Andrés Ortiz"
    },
    {
      "affiliations": [
        "Fundación Oftalmológica de Santander-Clínica Ardila Lülle, Universidad Autónoma de Bucaramanga, Floridablanca, Colombia"
      ],
      "name": "Carlos Ferreira Prada"
    },
    {
      "affiliations": [
        "Fundación Oftalmológica de Santander-Clínica Ardila Lülle, Universidad Autónoma de Bucaramanga, Floridablanca, Colombia"
      ],
      "name": "Oliverio Vargas Peréz"
    },
    {
      "affiliations": [
        "Fundación Oftalmológica de Santander-Clínica Ardila Lülle, Universidad Autónoma de Bucaramanga, Floridablanca, Colombia"
      ],
      "name": "Daniel Mantilla"
    }
  ],
  "title": "A232 Intravenous milrinone for prevention of delayed cerebral ischemia in aneurismatic subarachnoid hemorrhage",
  "uid": "50608f38-78e0-51fe-b1d9-3d55883be2bb"
}